Posted on 22 September 2011. Tags: ALZM
Current PPS: .437
Avg. 10day Vol: 350.2K
Outstanding Shares: 131.9M
ALZM’s medical team is divided into Allezoe Medical Holdings, who seeks the treatment of the Human Papillomavirus (HPV) while ALZM’s subsidiary, Aequorea Vision Medical, has developed patent pending medical technology for a “portable hypothermic, oxygenated preservation and transportation technology for human organs.
HPV is the most commonly sexually transmitted infection and leading cause of cervical cancer affecting an estimated 233 million women worldwide. ALZM’s patent pending medical technology “SureScreen” gives the ability to instantly identify HPV lesions with a 98% accuracy that then enables the medical provider to see the cell damage and provide immediate treatment to the patient. ALZM’s discovery is a major breakthrough and improvement to the traditional PAP-test that takes several days to give results, along with the delays of confirming an HPV diagnosis. ALZM’s technology will also provide an alternative HPV vaccine. ALZM’s developing vaccine will compliment Gardasil, the most common vaccine used today, to screen for HPV related damage that occurred before the vaccine was administered.
ALZM intends to have a straightforward, easy, and cost efficient option for patients who do not have the capabilities of completing the series of shots to prevent HPV and cervical cancer. In addition, ALZM is in final discussion to acquire a company with implant technologies for spinal surgery aiming to ease spinal and post-spinal surgery.
Sign Up for our Email Newsletter to get the Latest Updates ALZM!
© 2013 StockRockandRoll, LLC | All rights reserved